A Multicentre, Open-Label, Phase 2 Safety Extension Study to Evaluate the Safety and Tolerability of R-107 in subjects with Refractory Major Depressive Disorder.
Phase of Trial: Phase II
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs R 107 Radikal Therapeutics (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Acronyms BEDROC-1
- Sponsors Douglas Pharmaceuticals
- 15 Nov 2019 Planned End Date changed from 2 Oct 2020 to 4 Oct 2021.
- 17 May 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 19 Feb 2019 to 10 Jun 2019.
- 17 May 2019 Status changed from not yet recruiting to recruiting.